A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non–Transfusion-Dependent Alpha or Beta Thalassemia (ENERGIZE)
Фаза 3 – широко изпитване преди одобрение
Заболявания:
Non–Transfusion-Dependent Alpha- or Beta-Thalassemia
Спонсор: Agios Pharmaceuticals Inc.
Налично на:
БГ
Обобщение
Trial status: Authorised
Hemoglobin (Hb) response, defined as a ≥1.0 g/dL increase in average Hb concentration from Week 12 through Week 24 compared with baseline
Кой може да участва
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 86 participants
БГ
EN